These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11922858)

  • 41. Dopamine agonists.
    Factor SA
    Med Clin North Am; 1999 Mar; 83(2):415-43, vi-vii. PubMed ID: 10093586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The relevance of dopamine agonists in the treatment of depression].
    Clausius N; Born C; Grunze H
    Neuropsychiatr; 2009; 23(1):15-25. PubMed ID: 19272288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Principles of the pharmacological treatment of drug addiction].
    Saadan M; Scuvée-Moreau J; Seutin V
    Rev Med Liege; 2013; 68(5-6):245-51. PubMed ID: 23888572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bromocriptine-desipramine protocol in treatment of cocaine addiction.
    Giannini AJ; Billett W
    J Clin Pharmacol; 1987 Aug; 27(8):549-54. PubMed ID: 3308977
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Norepinephrine and stimulant addiction.
    Sofuoglu M; Sewell RA
    Addict Biol; 2009 Apr; 14(2):119-29. PubMed ID: 18811678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
    Benowitz NL
    Annu Rev Pharmacol Toxicol; 2009; 49():57-71. PubMed ID: 18834313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine D1/5 and D2/3 agonists differentially attenuate somatic signs of nicotine withdrawal in rats.
    Ohmura Y; Jutkiewicz EM; Zhang A; Domino EF
    Pharmacol Biochem Behav; 2011 Oct; 99(4):552-6. PubMed ID: 21624384
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New horizons for therapeutics in drug and alcohol abuse.
    Jupp B; Lawrence AJ
    Pharmacol Ther; 2010 Jan; 125(1):138-68. PubMed ID: 19917308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference.
    Gyertyán I; Gál K
    Neuroreport; 2003 Jan; 14(1):93-8. PubMed ID: 12544838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
    Linazasoro G;
    J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of cocaine abuse: pharmacotherapy.
    Kleber HD
    Ciba Found Symp; 1992; 166():195-200; discussion 200-6. PubMed ID: 1638913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature.
    Thobois S
    Clin Ther; 2006 Jan; 28(1):1-12. PubMed ID: 16490575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug abuse and therapy.
    McMillen BA
    Science; 1998 Jan; 279(5348):159-61. PubMed ID: 9446217
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacotherapy of cocaine abuse: preclinical development.
    Witkin JM
    Neurosci Biobehav Rev; 1994; 18(1):121-42. PubMed ID: 8170620
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Dopamine agonists--clinical applications beyond Parkinson's disease].
    Kuran W
    Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S54-8. PubMed ID: 17941460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
    Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
    Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.
    Keck TM; John WS; Czoty PW; Nader MA; Newman AH
    J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bromocriptine treatment for cocaine addiction: association with plasma prolactin levels.
    Gorelick DA; Wilkins JN
    Drug Alcohol Depend; 2006 Feb; 81(2):189-95. PubMed ID: 16051446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients.
    Margolin A; Avants SK; Kosten TR
    Am J Drug Alcohol Abuse; 1995 Nov; 21(4):469-81. PubMed ID: 8561098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse.
    Fehr C; Yakushev I; Hohmann N; Buchholz HG; Landvogt C; Deckers H; Eberhardt A; Kläger M; Smolka MN; Scheurich A; Dielentheis T; Schmidt LG; Rösch F; Bartenstein P; Gründer G; Schreckenberger M
    Am J Psychiatry; 2008 Apr; 165(4):507-14. PubMed ID: 18316420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.